Fmr LLC Invests $812,000 in Oxford Immunotec Global PLC (OXFD) Stock

Fmr LLC purchased a new stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $812,000.

A number of other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Oxford Immunotec Global by 2.4% in the third quarter. BlackRock Inc. now owns 1,310,098 shares of the company’s stock valued at $21,264,000 after acquiring an additional 30,774 shares during the last quarter. Granahan Investment Management Inc. MA lifted its stake in Oxford Immunotec Global by 9.1% in the second quarter. Granahan Investment Management Inc. MA now owns 565,332 shares of the company’s stock valued at $7,287,000 after acquiring an additional 47,159 shares during the last quarter. Northern Trust Corp lifted its stake in Oxford Immunotec Global by 3.1% in the second quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock valued at $3,423,000 after acquiring an additional 7,862 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Oxford Immunotec Global in the third quarter valued at $2,776,000. Finally, Russell Investments Group Ltd. lifted its stake in Oxford Immunotec Global by 19.7% in the second quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock valued at $1,257,000 after acquiring an additional 16,070 shares during the last quarter. Hedge funds and other institutional investors own 90.94% of the company’s stock.

In related news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at $139,500. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total transaction of $149,100.00. Following the transaction, the chief executive officer now directly owns 423,469 shares in the company, valued at $6,313,922.79. The disclosure for this sale can be found here. 6.61% of the stock is owned by corporate insiders.

Several brokerages have recently weighed in on OXFD. ValuEngine lowered shares of Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 1st. Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Thursday. BidaskClub raised shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Oxford Immunotec Global in a research report on Sunday, November 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $16.67.

Shares of OXFD opened at $14.90 on Friday. The stock has a market capitalization of $387.25 million, a PE ratio of -10.96 and a beta of 0.11. Oxford Immunotec Global PLC has a fifty-two week low of $10.00 and a fifty-two week high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings data on Friday, November 9th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.14). The company had revenue of $16.10 million during the quarter, compared to the consensus estimate of $33.60 million. Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. Oxford Immunotec Global’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.70) earnings per share. On average, sell-side analysts predict that Oxford Immunotec Global PLC will post -1.09 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by WKRB News and is owned by of WKRB News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/01/12/fmr-llc-invests-812000-in-oxford-immunotec-global-plc-oxfd-stock.html.

Oxford Immunotec Global Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

See Also: Why is Cost of Capital Important?

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply